Table 3 Demographic and clinical characteristics
US Participants | EU Participants | |||||
|---|---|---|---|---|---|---|
Dallas, TX (n = 9) | Chicago, IL (n = 7) | Total US (N = 16) | UK (n = 8) | France (n = 8) | Total EU (N = 16) | |
Age, mean (SD), y | 55.6 (4.3) | 56.4 (3.0) | 55.9 (3.7) | 53.3 (6.5) | 57.4 (4.5) | 55.3 (5.8) |
Race/ethnicity, n (%) | ||||||
White | 5 (55.6) | 4 (57.1) | 9 (56.3) | 8 (100) | NDa | NDa |
Black | 3 (33.3) | 3 (42.9) | 6 (37.5) | 0 | NDa | NDa |
Hispanic | 1 (11.1) | 0 | 1 (6.3) | 0 | NDa | NDa |
Highest education level | ||||||
High school/GED/secondary school | 1 (11.1) | 0 | 1 (6.3) | 3 (37.5) | 5 (62.5) | 8 (50.0) |
Some college | 3 (33.3) | 2 (28.6) | 5 (31.5) | – | – | – |
Associates degree (US) or vocational/technical qualifications completed (EU) | 1 (11.1) | 0 | 1 (6.3) | 3 (37.5) | 0 | 3 (18.8) |
Undergraduate degree | 3 (33.3) | 2 (28.6) | 5 (31.3) | 1 (12.5) | 2 (25.0) | 3 (18.8) |
Some graduate school | 1 (11.1) | 0 | 1 (6.3) | – | – | – |
Graduate/professional degree (US) or postgraduate qualification (EU) | 0 | 3 (42.9) | 3 (18.8) | 1 (12.5) | 1 (12.5) | 2 (12.5) |
BMI, n (%) | ||||||
< 25 kg/m2 | 2 (22.2) | 2 (28.6) | 4 (25.0) | 2 (25.0) | 3 (37.5) | 5 (31.3) |
25.0–29.99 kg/m2 (overweight) | 1 (11.1) | 2 (28.6) | 3 (18.8) | 2 (25.0) | 2 (25.0) | 4 (25.0) |
30.0–34.99 kg/m2 (obese class 1) | 2 (22.2) | 2 (28.6) | 4 (25.0) | 4 (50.0) | 2 (25.0) | 6 (37.5) |
35.0–39.99 kg/m2 (obese class 2) | 3 (33.3) | 1 (14.3) | 4 (25.0) | 0 | 1 (12.5) | 1 (6.3) |
≥ 40.0 (obese class 3) | 1 (11.1) | 0 | 1 (6.3) | 0 | 0 | 0 |
Comorbid conditions | ||||||
Hypertension | 2 (22.2) | 2 (28.6) | 4 (25.0) | 0 | 2 (25.0) | 2 (12.5) |
Mental health condition | 3 (33.3) | 0 | 3 (18.8) | 2 (25.0) | 1 (12.5) | 3 (18.8) |
Elevated cholesterol | 2 (22.2) | 1 (14.3) | 3 (18.8) | 2 (25.0) | 1 (12.5) | 3 (18.8) |
Type 2 diabetes | 1 (11.1) | 1 (14.3) | 2 (12.5) | 0 | 0 | 0 |
Family history of breast cancer | 3 (33.3) | 3 (42.9) | 6 (37.5) | 1 (12.5) | 1 (12.5) | 2 (12.5) |
Stroke/TIA | 0 | 0 | 0 | 1 (12.5) | 0 | 1 (6.3) |
Type of menopause | ||||||
Natural | 8 (88.9) | 7 (100) | 15 (93.8) | 8 (100) | 8 (100) | 16 (100) |
Surgicalb | 1 (11.1) | 0 | 1 (6.3) | 0 | 0 | 0 |
Cessation of menses due to breast cancer treatment | 0 | 0 | 0 | 0 | 0 | 0 |
HT use, n (%) | ||||||
Current user | 1 (11.1) | 0 | 1 (6.3) | 0 | 0 | 0 |
Previous user | 3 (33.3) | 3 (42.9) | 6 (37.5) | 0 | 2 (25.0) | 2 (12.5) |
Never used | 5 (55.6) | 4 (57.1) | 9 (56.3) | 8 (100) | 6 (75.0) | 14 (87.5) |